Beta-O2 ^Company

Beta-O2 Technologies Ltd. is a biomedical company, developing a proprietary implantable bioreactor, the ßAir, for the treatment of patients with type 1 Diabetes (T1D). ßAir was developed to address the main problems of the otherwise successful procedure in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and deterioration of functionality of the transplanted islets over time due to insufficient oxygen supply. It is a small medical device, which is implanted in a minimally invasive procedure.